RJA
ACOR

Raymond James & Associates’s Acorda Therapeutics ACOR Stock Holding History

Raymond James & Associates’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-95
Closed -$223K – 3733
2018
Q3 		$223K Sell
95
-880
-90% -$2.72M ﹤0.01% 3228
2018
Q2 		$3.36M Sell
975
-40
-4% -$122K 0.01% 1426
2018
Q1 		$2.88M Buy
1,015
+5
+0.5% +$15K 0.01% 1467
2017
Q4 		$2.6M Sell
1,010
-136
-12% -$387K ﹤0.01% 1522
2017
Q3 		$3.25M Buy
1,146
+646
+129% +$1.7M 0.01% 1314
2017
Q2 		$1.18M Buy
+500
New +$991K ﹤0.01% 1920
2017
Q1 		– Sell
-84
Closed -$189K – 3424
2016
Q4 		$189K Sell
84
-47
-36% -$112K ﹤0.01% 2898
2016
Q3 		$327K Sell
131
-17
-11% -$50.7K ﹤0.01% 2563
2016
Q2 		$454K Buy
148
+36
+32% +$117K ﹤0.01% 2160
2016
Q1 		$355K Sell
112
-8
-7% -$33.2K ﹤0.01% 2231
2015
Q4 		$614K Buy
120
+14
+13% +$61.2K ﹤0.01% 1882
2015
Q3 		$337K Buy
106
+9
+9% +$34.9K ﹤0.01% 2096
2015
Q2 		$388K Sell
97
-1
-1% -$3.86K ﹤0.01% 2198
2015
Q1 		$390K Sell
98
-7
-7% -$32.1K ﹤0.01% 2135
2014
Q4 		$516K Buy
+105
New +$451K ﹤0.01% 1925

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's ACOR Position: Q4 2018 in Review

Raymond James & Associates sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 95 shares — an estimated $223K sold.

Raymond James & Associates first reported a position in ACOR in Q4 2014 and held it in 15 quarters. The position peaked at $3.36M in Q2 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

  • Raymond James & Associates reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Raymond James & Associates sold 95 Acorda Therapeutics shares in Q4 2018, an estimated $223K.
  • Raymond James & Associates first reported a position in Acorda Therapeutics in Q4 2014 and held it in 15 quarters.
  • Raymond James & Associates's Acorda Therapeutics position peaked at $3.36M in Q2 2018.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.